A Double-blind, Randomized, Placebo-controlled, Cross-over, Allergen Challenge Study to Evaluate the Efficacy, Safety and Tolerability of BLX-028914 in Subjects With Allergic Rhinitis
This is a phase II study in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of two different oral doses of BLX-028914 in an allergen challenge model. BLX-028914, a selective phosphodiesterase-4 (PDE4) inhibitor with a promising safety profile,is currently under development for treatment of airway diseases by Orexo AB, Sweden.
The aim of this study is to compare the effect, safety and tolerability of 14 days treatment with BLX-0289014 in patients with SAR in an allergen challenge model versus placebo.
A double-blind, randomized, placebo-controlled, cross-over, allergen challenge study to evaluate the efficacy, safety and tolerability of BLX-028914 in subjects with allergic rhinitis
100 项与 BLX-028914 相关的临床结果
100 项与 BLX-028914 相关的转化医学
100 项与 BLX-028914 相关的专利(医药)
100 项与 BLX-028914 相关的药物交易